Drug & intervention

capmatinib

RxCUI 2362165

Clinical trials21

Recruiting1

Related conditions19

Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

21 shown

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)NCT05642572 · 2023-05-05

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET AlterationsNCT05567055 · 2023-10-03

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerNCT05488314 · 2022-12-13

ACTIVE_NOT_RECRUITING

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis TestNCT05243641 · 2022-08-18

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLCNCT04926831 · 2022-08-10

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping MutationNCT05435846 · 2022-08-10

RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)NCT05154344 · 2021-11-29

Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With CapmatinibNCT05675683 · 2021-10-01

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line TherapyNCT04816214 · 2021-09-22

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationNCT04677595 · 2021-05-17

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain MetastasesNCT04460729 · 2020-11-11

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationNCT04427072 · 2020-09-25

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping MutationsNCT04323436 · 2020-08-19

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%NCT04139317 · 2020-01-22

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).NCT03742349 · 2019-01-31

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung CancerNCT03647488 · 2018-12-26

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping MutationNCT03693339 · 2018-10-30

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneNCT03040973 · 2017-07-04

ACTIVE_NOT_RECRUITING

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)NCT02414139 · 2015-06-11

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.NCT02335944 · 2015-01-13

Managed Access Programs for INC280, CapmatinibNCT04741789

NO_LONGER_AVAILABLE

Conditions being studied

Carcinoma, Non-Small-Cell Lung6 Non-small Cell Lung Cancer3 Non Small Cell Lung Cancer2 Non-small Cell Lung Cancer (NSCLC)2 Advanced Solid Tumors Which Are cMET-dependent1 Breast Cancer1 Cancer1 Lung Cancer Metastatic1 MET Alterations1 MET Gene Mutation1 Metastatic Breast Cancer1 Metastatic Lung Non-Small Cell Carcinoma1 Metastatic Non-Small Cell Lung Cancer1 METex14 Mutations1 Non-small Cell Lung Carcinoma (NSCLC)1 Recurrent Lung Non-Small Cell Carcinoma1 Stage IV Lung Cancer1 Stage IV Lung Cancer AJCC v81 Triple Negative Breast Cancer (TNBC)1

Research locations

MadridSpain7 SeoulSouth Korea7 BarcelonaCatalonia, Spain6 CologneGermany6 BerlinGermany5 LeuvenBelgium5 LilleFrance5 SingaporeSingapore5 BostonMassachusetts, United States4 Los AngelesCalifornia, United States3 MarseilleFrance3 ParisFrance3

Leading sponsors

Novartis Pharmaceuticals14 Asan Medical Center1 Collin Blakely1 Intergroupe Francophone de Cancerologie Thoracique1 Janssen Research & Development, LLC1 M.D. Anderson Cancer Center1 SWOG Cancer Research Network1 Timothy Burns, MD, PHD1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.